Pay in 4 interest-free payments of $20.00 Learn more
Ships within 48 hours · Estimated delivery Jul 26 - Jul 31
is also a n aminofurazan-derived inhibitor of Akt kinases with potential antineoplastic activity
Bimatoprost elicits an immediate
UNC2281 inhibits steady-state Mer kinase phosphorylation with an IC50 value of 22 nM
InChiKey: CTQQKICGMSZCJL-AWEZNQCLSA-N
by rapid deesterification in animals and humans
Edoxaban - CAS# 480449-70-5 somer is also a n aminofurazan-derivedEdoxaban (INN, codenamed DU 176b, trade name Lixiana) is a potent, selective factor Xa inhibitor, which has good oral bioavailability. Edoxaban is an anticoagulant drug which acts as a direct factor Xa inhibitor. It is being developed by Daiichi Sankyo. It was approved in July 2011 in Japan for prevention of venous thromboembolisms (VTE) following lower limb orthopedic surgery. It was also approved by the FDA in January 2015 for the prevention of
US$ 2125.00
US$ 52.00
US$ 207.50
US$ 375.00
US$ 465.00
US$ 203.00
US$ 18.99